Trials / Completed
CompletedNCT00913549
To Demonstrate the Relative Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg Tablets
Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg Tablets
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Sandoz · Industry
- Sex
- Male
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
To demonstrate the relative bioequivalency study of dosage forms of Clemastine 2.68 mg tablets.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories) | |
| DRUG | Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.) |
Timeline
- Start date
- 1989-12-01
- Primary completion
- 1990-01-01
- Completion
- 1990-01-01
- First posted
- 2009-06-04
- Last updated
- 2017-03-28
Source: ClinicalTrials.gov record NCT00913549. Inclusion in this directory is not an endorsement.